Jeff Williamson to Coronary Disease
This is a "connection" page, showing publications Jeff Williamson has written about Coronary Disease.
Connection Strength
0.160
-
Margolis KL, Dunn K, Simpson LM, Ford CE, Williamson JD, Gordon DJ, Einhorn PT, Probstfield JL. Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: the antihypertensive and lipid lowering to prevent heart attack trial (ALLHAT-LLT). Am Heart J. 2009 Dec; 158(6):948-55.
Score: 0.078
-
Proschan M, Ford CE, Cutler JA, Graumlich JF, Pavlik V, Cushman WC, Davis BR, Alderman MH, Gordon D, Furberg CD, Franklin SS, Blumenthal SS, Castaldo RS, Preston RA. How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure? Stat Med. 2013 Feb 28; 32(5):884-97.
Score: 0.047
-
Margolis KL, Davis BR, Baimbridge C, Ciocon JO, Cuyjet AB, Dart RA, Einhorn PT, Ford CE, Gordon D, Hartney TJ, Julian Haywood L, Holtzman J, Mathis DE, Oparil S, Probstfield JL, Simpson LM, Stokes JD, Wiegmann TB, Williamson JD. Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Clin Hypertens (Greenwich). 2013 Aug; 15(8):542-54.
Score: 0.025
-
Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, Furberg CD. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet. 2000 Dec 09; 356(9246):1949-54.
Score: 0.010